merged_novo-nordisk-earnings-ozempic-wegovy.txt
<question_number>1</question_number>
<answer>N/A</answer>

<question_number>2</question_number>
<answer>N/A</answer>

<question_number>3</question_number>
<answer>N/A</answer>

<question_number>4</question_number>
<answer>N/A</answer>

<question_number>5</question_number>
<answer>N/A</answer>

<question_number>6</question_number>
<answer>N/A</answer>

<question_number>7</question_number>
<answer>N/A</answer>

<question_number>8</question_number>
<answer>N/A</answer>

<question_number>9</question_number>
<answer>N/A</answer>

<question_number>10</question_number>
<answer>N/A</answer>

<question_number>11</question_number>
<answer>7.14 Danish kroner per U.S. dollar</answer>
<other>290 billion Danish kroner = $40.6 billion, so 290/40.6 = 7.14 Danish kroner per U.S. dollar</other>

<question_number>12</question_number>
<answer>CagriSema</answer>

<question_number>13</question_number>
<answer>President Trump's election</answer>

<question_number>14</question_number>
<answer>Novo Nordisk</answer>

<question_number>15</question_number>
<answer>16 percent</answer>

<question_number>16</question_number>
<answer>40 percent</answer>

<question_number>17</question_number>
<answer>2</answer>
<other>Ozempic and Wegovy are explicitly named</other>

<question_number>18</question_number>
<answer>United States</answer>

<question_number>19</question_number>
<answer>European Union</answer>

<question_number>20</question_number>
<answer>Geopolitics</answer>